Manish Butte
Pediatric Allergy/Immunology · Los Angeles, CANPI 1801861216
Payments from drug & device makers
Across 450 payments — averaging $2529.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$320K
- Takeda Pharmaceuticals U.S.A., Inc.$216K
- Pharming Healthcare, Inc.$157K
- Grifols USA, LLC$149K
- CSL Behring$96K
- Chiesi USA, Inc.$77K
- plus $123K from 17 others
Across 4 payments — averaging $6740.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharming Healthcare, Inc.$27K
What the payments were for
- Consulting fees$69,50719%
- Speaking & faculty fees$227,94364%
- Travel & lodging$44,02112%
- Food & beverage$15,2394%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 4 | $320,331 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $216,085 |
| Pharming Healthcare, Inc. | 61 | $156,968 |
| Grifols USA, LLC | 142 | $149,104 |
| CSL Behring | 88 | $95,606 |
| Chiesi USA, Inc. | 14 | $77,324 |
| Swedish Orphan Biovitrum AB | 11 | $32,566 |
| Regeneron | 10 | $32,404 |
| Amgen(2 entities) | 38 | $22,176 |
| Octapharma USA, Inc. | 6 | $15,920 |
| Sanofi | 13 | $11,159 |
| ADMA Biomanufacturing LLC | 16 | $4,769 |
| Grifols Shared Services North America, Inc. | 20 | $2,635 |
| AstraZeneca | 2 | $183 |
| Regeneron Healthcare Solutions, Inc. | 4 | $182 |
| Incyte Corporation | 2 | $144 |
| LEO Pharma Inc. | 1 | $134 |
| Blueprint Medicines Corporation | 1 | $132 |
| GSK | 1 | $121 |
| Sobi, Inc | 2 | $108 |
| X4 Pharmaceuticals, Inc. | 1 | $106 |
| Dermavant Sciences, Inc. | 1 | $67 |
| Jubilant Hollisterstier LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,138,246 in reported general payments places this provider in the 95th percentile of 48 pediatric allergy/immunology providers in California.
See all pediatric allergy/immunology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $116,174 |
| Doxycycline Hyclate | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $95,606 | $116,17417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 pediatric allergy/immunology providers in California.
Other pediatric allergy/immunology in Los Angeles
- Peck OngLos Angeles$568K
- Neema IzadiLos Angeles$185K
- Maria Garcia-LloretLos Angeles$135K
- Talal ChatilaLos Angeles$30K
- Ewald StiehmLos Angeles$24K
- Elizabeth FeuilleLos Angeles$6K
- Marilyn LiLos Angeles$5K
- Caroline KuoLos Angeles$418
- Joseph ChurchLos Angeles$222
- Stephanie RodriguezLos Angeles$157
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.